Get the Daily Brief
Latest Biotech News
NeoGenomics Stock Dips After Revenue Miss and Lowered 2025 Guidance Amid Competitive Challenges
NeoGenomics reported a 10% growth in second-quarter 2025 revenues to $181.3 million, but results fell short of analyst expectations. The company lowered its full-year revenue and earnings...
Virtual Laboratory AI Agents Accelerate Complex Biomedical Research with Interdisciplinary Collaboration
Researchers from Stanford University and Chan Zuckerberg Biohub have developed an innovative AI-driven “Virtual Lab” system that mimics a multidisciplinary scientific team led by a principal...
Celcuity's Breast Cancer Therapy Gedatolisib Delivers Breakthrough Phase III Results – Stock Soars
Minneapolis-based Celcuity announced positive top-line data from its phase III Viktoria-1 study evaluating gedatolisib in combination with standard treatments for HR-positive, HER2-negative,...
Trade Deal Imposes 15% Tariffs on Pharma Imports in US-EU Agreement – Industry Impacts Weighed
The new trade agreement between the United States and the European Union includes a 15% tariff on pharmaceutical imports, marking a significant departure from previous zero-duty policies. Analysts...
FDA Clears Sarepta’s Duchenne Therapy Shipments for Ambulatory Patients
The FDA reversed its earlier hold and has authorized Sarepta Therapeutics to promptly resume shipments of Elevidys, its gene therapy for ambulatory Duchenne muscular dystrophy (DMD) patients. This...
Merck’s $3B Cost-Cutting Drive Signals Strategic Shift Amid Pipeline Challenges
Merck & Co. announced a comprehensive cost-saving initiative aiming to cut $3 billion annually by 2027, alongside a strategic shift focusing investment on newer product launches and pipeline...
Novo Nordisk Faces Sales Downgrade as CEO Changes Amid Obesity Drug Competition
Danish pharmaceutical leader Novo Nordisk announced significant downward revisions to its 2025 sales and operating profit forecasts due to competition from low-cost semaglutide knockoffs impacting...
Celcuity Breast Cancer Drug Shakes Market After Positive Phase III Results
Celcuity reported strong phase III clinical results for gedatolisib in combination therapies targeting hormone receptor-positive, HER2-negative breast cancer lacking PI3KCA mutations. The therapy...
GSK and Hengrui Ink $12.5 Billion Collaboration for Respiratory and Oncology Assets
GSK plc expanded its respiratory and immunology portfolio through a strategic partnership with Hengrui Pharmaceuticals. The deal includes a $500 million upfront payment for an exclusive global...
GeneDx Reports Surge in Genome and Exome Testing Revenues, Boosts 2025 Guidance
Gaithersburg-based genetic diagnostics company GeneDx reported a 49% year-over-year revenue increase in Q2 2025 to $102.7 million, driven largely by whole-exome and whole-genome testing which...
Apellis’ Empaveli Gains FDA Approval for Rare Kidney Diseases
Apellis Pharmaceuticals received FDA approval for an expanded indication of its complement 3 (C3) inhibitor pegcetacoplan, marketed as Empaveli, for two rare kidney disorders: complement 3...
Boehringer and Re-Vana Partner in Eye Health with Potential $1B Deal
Boehringer Ingelheim has expanded its ophthalmology portfolio by entering a collaboration with Re-Vana Therapeutics to develop extended-release ocular therapies. The potential partnership, valued...
AI and Computational Innovations Propel Biotech Research and Diagnostics
Advances in AI and computational technologies are reshaping biotech R&D and diagnostics. NIH researchers unveiled GeneAgent, an LLM-powered gene-set analysis tool that autonomously verifies...
Bayer, Bristol Myers, and Bain Drive Pharma Portfolio Reshaping and Financing
Bayer aims to revive growth through new drug launches as key products like Xarelto and Eylea plateau. Bristol Myers Squibb is realigning its pipeline by transferring five immunology assets,...
Sarepta's Duchenne gene therapy shipment reversal
The FDA has reversed its recent halt on Sarepta Therapeutics’ gene therapy Elevidys for ambulatory patients with Duchenne muscular dystrophy (DMD) following an investigation that concluded an...
Novo Nordisk cuts guidance amid leadership change
Novo Nordisk dramatically reduced its 2025 sales growth forecast to 8%-14% from a previous 13%-21%, citing ongoing challenges from lower sales of popular GLP-1 drugs due to knockoff competition....
Merck initiates $3B cost-cutting to refocus portfolio
Merck announced a sweeping initiative to save $3 billion annually by 2027, redirecting funds from mature products to support new launches and its experimental pipeline. The program involves...
Celcuity's breast cancer drug charts phase III success
Minneapolis biotech Celcuity reported positive phase III results for its breast cancer therapy gedatolisib, which demonstrated significant progression-free survival benefits in hormone...
GSK and Hengrui's $12.5B drug collaboration
GlaxoSmithKline inked a significant licensing deal with China’s Hengrui Pharmaceuticals for up to $12.5 billion, gaining rights to 12 drug assets including HRS-9821, a PDE3/4 inhibitor targeting...
GeneDx reports strong growth and raised revenue outlook
Genetic testing firm GeneDx posted a 49% increase in Q2 revenue driven by higher volumes of whole-exome and whole-genome sequencing tests, marking its fourth consecutive profitable quarter. The...